Prostate Adenocarcinoma, TMPRSS2::ETV1 Fusion-Positive: Two Cases with Clinical and Molecular Characterization

被引：0
|
作者：
Bubar, R. [1 ]
Korentzelos, D. [1 ]
Wald, A. [1 ]
Tucker, J. [1 ]
Mohebnasab, M. [1 ]
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2024年 / 26卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
ST130
引用
收藏
页码：S133 / S133
页数：1
相关论文
共 50 条
  • [1] Fusion Between TMPRSS2 and ETS Family Members (ERG, ETV1, ETV4) in Prostate Cancers from Northern China
    Wang, Jian-Jiang
    Liu, Yue-Xin
    Wang, Wei
    Yan, Wei
    Zheng, Yu-Peng
    Qiao, Lu-Dong
    Liu, Dan
    Chen, Shan
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (10) : 4935 - 4938
  • [2] Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
    Li, Chengxun
    Zhang, Jiale
    Wu, Qiming
    Kumar, Anuj
    Pan, Guihong
    Kelvin, David J.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (03) : 306 - 316
  • [3] Body size and incidence of TMPRSS2:ERG fusion-positive and fusion-negative prostate cancer
    Ahearn, Thomas
    Graff, Rebecca E.
    Pettersson, Andreas
    Pernar, Claire
    Markt, Sarah C.
    Wilson, Kathryn M.
    Fiorentino, Michelangelo
    Loda, Massimo
    Giovannucci, Edward L.
    Mucci, Lorelei A.
    CANCER RESEARCH, 2016, 76
  • [4] Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer
    Haydn Thomas Kissick
    Martin George Sanda
    Laura Kathleen Dunn
    Mohamed Simo Arredouani
    Cancer Immunology, Immunotherapy, 2013, 62 : 1831 - 1840
  • [5] Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer
    Kissick, Haydn Thomas
    Sanda, Martin George
    Dunn, Laura Kathleen
    Arredouani, Mohamed Simo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (12) : 1831 - 1840
  • [6] miR-221 Is Down-regulated in TMPRSS2:ERG Fusion-positive Prostate Cancer
    Gordanpour, Aida
    Stanimirovic, Aleksandra
    Nam, Robert K.
    Moreno, Carlos S.
    Sherman, Christopher
    Sugar, Linda
    Seth, Arun
    ANTICANCER RESEARCH, 2011, 31 (02) : 403 - 410
  • [7] Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion-positive prostate cancer
    Yun, Jae Won
    Lee, Sejoon
    Chun, Sejong
    Lee, Kwang Woo
    Kim, Jongsu
    Kim, Hong Sook
    CLINICAL AND TRANSLATIONAL MEDICINE, 2021, 11 (05):
  • [8] Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers
    Luebke, Andreas M.
    Ricken, Wiebke
    Kluth, Martina
    Hube-Magg, Claudia
    Schroeder, Cornelia
    Buescheck, Franziska
    Moeller, Katharina
    Dum, David
    Hoeflmayer, Doris
    Weidemann, Soeren
    Fraune, Christoph
    Hinsch, Andrea
    Wittmer, Corinna
    Schlomm, Thorsten
    Huland, Hartwig
    Heinzer, Hans
    Graefen, Markus
    Haese, Alexander
    Minner, Sarah
    Simon, Ronald
    Sauter, Guido
    Wilczak, Waldemar
    Meiners, Jan
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (02) : 575 - 583
  • [9] Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors
    Geybels, Milan S.
    Alumkal, Joshi J.
    Luedeke, Manuel
    Rinckleb, Antje
    Zhao, Shanshan
    Shui, Irene M.
    Bibikova, Marina
    Klotzle, Brandy
    van den Brandt, Piet A.
    Ostrander, Elaine A.
    Fan, Jian-Bing
    Feng, Ziding
    Maier, Christiane
    Stanford, Janet L.
    CLINICAL EPIGENETICS, 2015, 7
  • [10] Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors
    Milan S. Geybels
    Joshi J. Alumkal
    Manuel Luedeke
    Antje Rinckleb
    Shanshan Zhao
    Irene M. Shui
    Marina Bibikova
    Brandy Klotzle
    Piet A. van den Brandt
    Elaine A. Ostrander
    Jian-Bing Fan
    Ziding Feng
    Christiane Maier
    Janet L. Stanford
    Clinical Epigenetics, 2015, 7
12345